

#### Health Economics Research Centre



Nuffield Department of Population Health

#### Health policy model with R

Iryna Schlackow
on behalf of the SHARP Collaborative Group

NHS-R Community Conference 2019
Birmingham, November 5, 2019

## Motivation: what is a health policy model?

A <u>health policy model</u> is a tool to inform policy decisions by projecting people's life courses. Predictions include

- disease events
- life expectancy
- quality of life
- healthcare costs
- effects of treatments
  - positive (disease risk reduction) and negative (adverse effects)

Projections made over long time periods (eg lifetime)



### Motivation: why are health policy models needed?

Healthcare budgets are limited and not all treatments can be recomended even if effective

- Models show whether treatments are good value for money
- Health policy models are increasingly used by policy makers and clinicians
- In UK, cost-effectiveness analyses are required by NICE
  - Good-value-for-money: £20-30K per additional quality-adjusted life-year (QALY)
- Flexible models can help answer many policy questions
- Aim for transparency, reliability, reproducibility and usability



## Case study: SHARP CKD-CVD model Background

- Chronic kidney disease (CKD) increases cardiovascular (CV) risk
- Want to project long-term outcomes in CKD
  - cardiovascular events, CKD progression, life expectancy, quality of life, healthcare costs;
  - enable implementation of treatments to reduce cardiovascular risk
    - assess long-term effects and cost-effectiveness.
- Patient-level data from a trial
  - baseline characteristics, within-trial events
- Risk equations derived from the data
- Combined into a Markov model to do lifelong projections
  - validated internally and externally



### SHARP CKD-CVD model: Computational challenges and solutions

- Due to complex structure (68 states), initial run on 10,000 patients took >24 hours even without uncertainty.
- Ways to optimise the algorithm:
  - Parallel programming across patients
  - Reducing size of transitional matrices
    - Remove rows corresponding to disallowed transitions / starting states (as opposed to setting them to 0)
- Only basic R functionality was used
  - 9 packages: data manipulation (reshape2, plyr, data.table); parallel programming (foreach, snowfall, doSNOW); plotting and saving (xtable, scales, ggplot2)
  - No specific CEA packages (hence fine-tuning possible)
- Simple tinkering reduced the time to 50 minutes




## SHARP CKD-CVD model: need for a user-friendly interface

- The model to be useful for NICE, other analysts, clinicians...
- User-friendly interface accessible from anywhere
- No need for knowledge / installation of R
- Adaptation to other scenarios/countries
  - national mortality rates
  - national healthcare costs
- Customising parameters in the current setting
  - treatment to be assessed
  - population characteristics
  - duration of treatment / time horizon
  - discount rate



## SHARP CKD-CVD model: Shiny interface




http://one-elevenbooks.com/shiny-or-the-truth/

- Application accessed via a link
- The user only sees the front end
- All programs/data stored externally
- The front end can be modified using CSS themes, htmlwidgets, and JavaScript actions
  - fancy fonts, links, email addresses etc
  - error checking on data entry

http://dismod.ndph.ox.ac.uk/kidneymodel/app/




## SHARP CKD-CVD model: Shiny interface





### SHARP CKD-CVD model:


Shiny interface






### SHARP CKD-CVD model:

Shiny interface






## SHARP CKD-CVD model: Shiny interface






# SHARP CKD-CVD model: Shiny interface





### SHARP CKD-CVD model:

Shiny interface






### SHARP CKD-CVD model:

Shiny interface

SHARP CKD-CVD outcon ×					
← → C ① dismod.ndph.ox.ac.uk/kidneymodel/app/					
SHARP CKD-CVD outcomes model (beta version)					
	The default values are based on SHARP data and UK 2014 prices.				
Introduction	Reset inputs				
Model overview	The default costs for the probabilistic sensitivity analyses are derived from the SHARP data using the bootstrap				
Glossary	method. To provide alternative costs, enter the means and the standard errors below, and the costs will be sampled from gamma distributions. The displayed values are based on SHARP data and UK 2014 prices [1].				
File specifications	Annual cost of CKD				
Model parameters	CKD stage 3B				
Woder parameters	mean estimate	standard error			
Type of analysis	427	32			
Patient characteristics	CKD stage 4				
Treatment parameters	mean estimate	standard error			
Annual healthcare costs	417	27			
Health-related quality of life	CKD stage 5				
Non-vascular death probabilities	mean estimate	standard error			
Hon vascalar acath probabilities	556	41			
Decision parameters	On dialysis, for year of dialysis initiati	00			
Analyses	On dialysis, for year of dialysis initiation  mean estimate standard error				
Results	20112	198			
	On dialysis, not for year of dialysis initiation				
	mean estimate	standard error			
	24709	51			
4		· ·			



## SHARP CKD-CVD model: Shiny interface





#### Discount cost-effectiveness results

Long-term projections in the control group (cumulative probabilities per 1,000 participants)


		MVE or VD	RRT	Vascular deaths	All deaths
	At 5 years	184 (159, 213)	409 (357, 444)	57 (44, 76)	205 (194, 222)
	At 10 years	281 (244, 319)	643 (594, 683)	118 (92, 155)	415 (398, 438)
	Over simulation duration	419 (358, 501)	884 (826, 935)	292 (225, 379)	907 (897, 918)

Long-term projections in the treatment group (cumulative probabilities per 1,000 participants)

	MVE or VD	RRT	Vascular deaths	All deaths
At 5 years	169 (138, 193)	407 (355, 439)	51 (37, 70)	200 (189, 216)
At 10 years	283 (214, 299)	638 (593, 675)	108 (81, 140)	407 (389, 429)
Over simulation duration	397 (328, 477)	877 (813, 927)	271 (207, 371)	905 (896, 915)

Incremental cost-effectiveness over the simulation duration (results per 1,000 participants)

LYs gained	QALYs gained	Incremental hospital costs	Treatment costs	Cost per LY gained	Cost per QALY gained
135 (-4, 279)	107 (22, 227)	698,152 (-416,384, 1,306,000)	5,074,512 (4,904,776, 5,201,336)	42,646 (20,617, 304,068)	54,085 (27,412, 179,555)



## User-friendly interface: help with debugging and transparency

- Face validity debugging
  - Easier to do on a user-friendly interface (even for the developers!)
- Feedback from external users
- Running several models against a reference simulation
  - Mount Hood diabetes challenge: models predicting long-term outcomes in diabetes patients
    - everyone gets the same tasks (eg change in life expectancy after statin initiation)
    - core assumptions same for everyone
    - additional assumptions must be documented in a pre-defined template
    - the results are presented, compared and (usually) published
    - user-friendly interface enables replication



### SHARP CKD-CVD model: conclusions

- SHARP CKD-CVD model is a novel resource for evaluating health outcomes and cost-effectiveness of interventions in CKD
- Efficient coding is important and much can be achieved using basic functionality only
- User-friendly web-based freely available interface aids model use
- Together with the published equations / methods helps ensure reliability of the underlying code and methods transparency
- Using R was paramount in model development process
  - Wrapping code chunks in functions
  - Straightforward debugging
  - Parallel programming
  - Shiny interface



### SHARP CKD-CVD model: Remaining challenges and discussion points

- Day-to-day support
  - Replying to queries, fixing bugs
  - R/package updates may break everything!
  - Not updating is not an option (according to our IT team)
- Is R the best option for such an interface?
  - Might another language(s) be faster and/or have better visualisation capabilities?
- Do the benefits of releasing the code outweigh the risks?




### Acknowledgements

- Boby Mihaylova
- Seamus Kent, Richard Haynes, Jonathan Emberson, Will Herrington, Colin Baigent, Alastair Gray, Jingky Lozano-Kuehne, Martin Craig, Martin Landray, Kirsty Reith
- SHARP participants, study staff and collaborators!
- The SHARP study was funded by Merck/Schering- Plough Pharmaceuticals (North Wales, PA, USA), with additional support from the Australian National Health Medical Research Council, the British Heart Foundation, and the UK Medical Research Council



#### SHARP CKD-CVD model



http://dismod.ndph.ox.ac.uk/kidneymodel/app/

iryna.schlackow@ndph.ox.ac.uk



